The role of Wnt signaling in cancer and stem cells

Future Oncology

Volumn 1, Issue 6, 2005, Pages 787-797

  Reguart, Noemi ^a   He, Biao ^b   Taron, Miquel ^a   You, Liang ^b   Jablons, David M ^b   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

catenin; adenomatous polyposis coli; cancer; dishevelled; secreted Frizzled related protein; stem cells; Wnt inhibitory factor beta

Indexed keywords

WNT PROTEIN;

ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; STEM CELLS; WNT PROTEINS;

EID: 33845303957     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.787     Document Type: Review

References (119)

1. Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R: The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50, 649-657 (1987).
2. Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99-109 (1982).
3. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J. Cell. Sci. 116, 2627-2634 (2003).
4. Miller JR: The Wnts. Genome Biol. 3, 3001 (2002).
5. Polakis P: Wnt signaling and cancer. Genes Dev. 14, 1837-1851 (2000).
6. Lustig B, Behrens J: The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 129, 199-221 (2003).
7. Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT: Dishevelled activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. J. Cell Biol. 161, 769-777 (2003).
8. Cohen ED, Mariol MC, Wallace RM et al.: DWnt4 regulates cell movement and focal adhesion kinase during Drosophila ovarian morphogenesis. Dev. Cell. 2, 437-448 (2002).
9. Boutros M, Paricio N, Strutt D I, Mlodzik M: Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. Cell 94, 109-118 (1998).
10. Ciani L, Krylova O, Smalley MJ, Dale TC, Salinas PC: A divergent canonical WNTsignaling pathway regulates microtubule dynamics: Dishevelled signals locally to stabilize microtubules. J. Cell Biol. 164, 243-253 (2004).
11. He B, Lee AY, Dadfarmay S et al.: Secreted Frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in a-catenin-deficient human mesothelioma cells. Cancer Res. 65, 743-748 (2005).
12. Lee AY, He B, You L et al.: Dickkopf-1 antagonizes Wnt signaling independent of a-catenin in human mesothelioma. Biochem. Biophys. Res. Commun. 323, 1246-1250 (2004).
13. You L, He B, Uematsu K et al.: Inhibition of Wnt-1 signaling induces apoptosis in a- catenin-deficient mesothelioma cells. Cancer Res. 64, 3474-3478 (2004).
14. Rhee CS, Sen M, Lu D et al.: Wnt and Frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21, 6598-6605 (2002).
15. Simon M, Grandage VL, Linch DC, Khwaja A: Constitutive activation of the Wnt/a-catenin signalling pathway in acute myeloid leukaemia. Oncogene 24, 2410-2420 (2005).
16. Lu D, ZhaoY, Tawatao R et al.: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 101, 3118-3123 (2004).
17. Morin PJ, Sparks AB, KorinekW et al.: Activation of a-catenin-Tcf signaling in colon cancer by mutations in a-catenin or APC. Science 275, 1787-1790 (1997).
18. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P: Stabilization of a-catenin by genetic defects in melanoma cell lines. Science 275, 1790-1792 (1997).
19. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER: Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325-329 (1999).
20. Howe LR, Brown AM: Wnt signaling and breast cancer. Cancer Biol. Ther. 3, 36-41 (2004).
21. Kuhnen C, Herter P, Muller O et al.: a-catenin in soft tissue sarcomas: expression is related to proliferative activity in highgrade sarcomas. Mod. Pathol. 13, 1005-1013 (2000).
22. Mao J, Wang J, Liu B et al.: Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell. 7, 801-809 (2001).
23. Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J, Nusse R: The Dishevelled protein is modified by Wingless signaling in Drosophila. Genes Dev. 9, 1087-1097 (1995).
24. Wharton KA: Runnin with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev. Biol. 253, 1-17 (2003).
25. Itoh K, Brott BK, Bae G, Ratcliffe MJ, Sokol SY: Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. J. Biol. 4, 3 (2005).
26. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW: Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem. 272, 24735-24738 (1997).
27. Amit S, Hatzubai A, BirmanY et al.: Axinmediated CKI phosphorylation of a- catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076 (2002).
28. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3a and a-catenin and promotes GSK-3a-dependent phosphorylation of a-catenin. EMBO J. 17, 1371-1384 (1998).
29. Behrens J, Jerchow BA, Wurtele M et al.: Functional interaction of an axin homolog, conductin, with a-catenin, APC, and GSK3a. Science 280, 596-599 (1998).
30. Liu C, Li Y, Semenov, M et al.: Control of a-catenin phosphorylation/ degradation by a dual-kinase mechanism. Cell 108, 837-847 (2002).
31. Itoh K, Antipova A, Ratcliffe JM, Soko S: Interaction of dishevelled and Xenopus axinrelated protein is required for Wnt signal transduction. Mol. Cell. Biol. 20(6), 2228-2238 (2000).
32. Yang-Snyder J, Miller JR, Brown JD, Lai CJ, Moon RT: A Frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol. 6(10), 1302-1306 (1996).
33. Roose J, Molenaar M, Peterson J et al.: The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395, 608-612 (1998).
34. Eastman Q, Grosschedl R: Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell. Biol. 11, 233-240 (1999).
35. Behrens J, von Kries JP, Kuhl M et al.: Functional interaction of a-catenin with the transcription factor LEF-1. Nature 382, 638-642 (1996).
36. He TC, Sparks AB, Rago C et al.: Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
37. Tetsu O, McCormick F: a-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426 (1999).
38. Kramps T, Peter O, Brunner E et al.: Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 109, 47-60 (2002).
39. Townsley FM, Cliffe A, Bienz M: Pygopus and Legless target Armadillo/a-catenin to the nucleus to enable its transcriptional coactivator function. Nature Cell Biol. 6(7), 626-633 (2004).
40. Hoffmans R, Stdeli R, Basler K: Pygopus and legless provide essential transcriptional coactivator functions to Armadillo/a-catenin. Curr. Biol. 15(13), 1207-1211 (2005).
41. Katoh M: Expression and regulation of WNT1 in human cancer: upregulation of WNT1 by a-estradiol in MCF-7 cells. Int. J. Oncol. 22, 209-212 (2003).
42. Wong SC, Lo SF, Lee KC et al.: Expression of frizzled-related protein and Wntsignalling molecules in invasive human breast tumours. J. Pathol. 196, 145-153 (2002).
43. He B, You L, Uematsu K et al.: A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6, 7-14 (2004).
44. Roelink H, Wagenaar E, Nusse R: Amplification and proviral activation of several Wnt genes during progression and clonal variation of mouse mammary tumors. Oncogene 7, 487-492 (1992).
45. Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P: Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified proto oncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer 23, 307-316 (1998).
46. Katoh M, Kirikoshi H, Terasaki H, Shiokawa K: WNT2B2 mRNA, upregulated in primary gastric cancer, is a positive regulator of the WNT-a-catenin-TCF signaling pathway. Biochem. Biophys. Res. Commun. 289, 1093-1098 (2001).
47. Vider BZ, Zimber A, Chastre E et al.: Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene 12, 153-158 (1996).
48. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T: Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol. Pathol. 55, 220-226 (2002).
49. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF: Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol. Pathol. 56, 280-285 (2003).
50. You L, He B, Xu Z et al.: Inhibition of Wnt- 2-mediated signaling induces programmed cell death in non-small cell lung cancer cells. Oncogene 23, 6170-6174 (2004).
51. Moon RT, Brown JD, Torres M: WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. 13, 157-162 (1997).
52. Liang H, Chen Q, Coles AH et al.: Wnt5a inhibits B-cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349-360 (2003).
53. Weeraratna AT, Jiang Y, Hostetter G et al.: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288 (2002).
54. Nakano T, Tani M, Ishibashi Y et al.: Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin. Exp. Metastasis 20, 665-674 (2003).
55. Calvo R, West J, Franklin W et al.: Altered HOX and WNT7A expression in human lung cancer. Proc. Natl Acad. Sci. USA 97, 12776-12781 (2000).
56. Winn RA, Marek L, Han SY et al.: Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through Frizzled-9-mediated growth gnhibition and promotion of cell differentiation. J. Biol. Chem. 280, 19625-19634 (2005).
57. Fedi P, Bafico A, Nieto Soria A et al.: Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem. 274, 19465-19472 (1999).
58. Jones SE, Jomary C: Secreted Frizzledrelated proteins: searching for relationships and patterns. Bioessays 24, 811-820 (2002)
59. Zhou Z, Wang J, Han X, Zhou J, Linder S: Upregulation of human secreted frizzled homolog in apoptosis and its downregulation in breast tumors. Int. J. Cancer 78, 95-99 (1998).
60. Ko J, Ryu KS, Lee H et al.: Human secreted frizzled-related protein is downregulated and induces apoptosis in human cervical cancer. Exp. Cell. Res. 280, 280-287 (2002).
61. Suzuki H, Watkins DN, Jair KW et al.: Epigenetic inactivation of SFRP genes allows constitutive Wnt signaling in colorectal cancer. Nature Genet. 36, 417-422 (2004).
62. To KF, Chan MW, Leung WK et al.: Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci. 70, 483-489 (2001).
63. Lee AY, He B, You L et al.: Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23, 6672-6676 (2004).
64. Taketo MM: Shutting down Wnt signalactivated cancer. Nature Genet. 36, 320-322 (2004).
65. Hsieh JC, Kodjabachian L, Rebbert ML et al.: A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431-436 (1999).
66. Wissmann C, Wild PJ, Kaiser S et al.: WIF1, a component of the Wnt pathway, is downregulated in prostate, breast, lung, and bladder cancer. J. Pathol. 201, 204-212 (2003).
67. Mazieres J, He B, You L et al.: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64, 4717-4720, (2004).
68. Zorn AM: Wnt signalling: antagonistic Dickkopfs. Curr. Biol. 11, R592-R595 (2001).
69. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, Srivenugopal KS: Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21, 878-889 (2002).
70. Gonzalez-Sancho JM, Aguilera O, Garcia JM et al.: The Wnt antagonist DICKKOPF-1 gene is a downstream target of a-catenin/TCF and is downregulated in human colon cancer. Oncogene 24, 1098-1103 (2005).
71. Hsieh SY, Hsieh PS, Chiu CT, Chen WY: Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23, 9183-9189 (2004).
72. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis, P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272(5264), 1023-1026 (1996).
73. Behrens J, Lustig B: The Wnt connection to tumorigenesis. Int. J. Dev. Biol. 48, 477-487 (2004).
74. Fodde R: The APC gene in colorectal cancer. Eur. J. Cancer 38, 867-871 (2002).
75. Moreno-Bueno G, Hardisson D, Sanchez C et al.: Abnormalities of the APC/betacatenin pathway in endometrial cancer. Oncogene 21, 7981-7990 (2002).
76. Schlosshauer PW, Pirog EC, Levine RL, Ellenson LH: Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod. Pathol. 13, 1066-1071 (2000).
77. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S: a-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 58, 3526-3528 (1998).
78. Gerstein AV, Almeida TA, Zhao G et al.: APC/CTNNB1 (a-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34, 9-16 (2002).
79. de La Coste A, Romagnolo B, Billuart P et al.: Somatic mutations of the a-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA 95, 8847-8851 (1998).
80. Taniguchi K, Roberts RL, Aderca IN et al. Mutational spectrum of a-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21(31), 4863-4871 (2002).
81. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet. 24(3), 245-250 (2000).
82. Wetering MV, Sancho E, Verweij C et al. The a-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111(2), 241-250 (2002).
83. Sansom OJ, Reed KR, Hayes AJ et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18(12), 1385-1390 (2004).
84. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM: Activation of the Wnt pathway in non-small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22, 7218-7221 (2003).
85. Uematsu K, Kanazawa S, You L et al.: Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of a-catenin. Cancer Res. 63, 4547-4551 (2003).
86. Nagahata T, Shimada T, Harada A et al.: Amplification, upregulation and overexpression of DVL-1, the human counterpart of the Drosophila |Disheveled gene, in primary breast cancers. Cancer Sci. 94, 515-518 (2003).
87. Zechner D, Fujita Y, Hulsken J et al.: a-catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev. Biol. 258, 406-418 (2003).
88. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3- specific inhibitor. Nature Med. 10, 55-63 (2004).
89. Muroyama Y, Kondoh H, Takada S: Wnt proteins promote neuronal differentiation in neural stem cell culture. Biochem. Biophys. Res. Commun. 313, 915-921 (2004).
90. Brandon C, Eisenberg LM, Eisenberg CA: WNT signaling modulates the diversification of hematopoietic cells. Blood 96, 4132-4141 (2000).
91. Kielman MF, Rindapaa M, Gaspar C et al.: Apc modulates embryonic stem-cell differentiation by controlling the dosage of a-catenin signaling. Nature Genet. 32, 594-605 (2002).
92. Reya T, Duncan AW, Ailles L et al.: A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409-414 (2003).
93. Van Den Berg DJ, Sharma AK, Bruno E, Hoffman R: Role of members of the Wnt gene family in human hematopoyesis. Blood 92(9), 3189-3202. (1998).
94. Cobas M, Wilson A, Ernst B et al.: a- catenin is dispensable for hematopoiesis and lymphopoiesis. J. Exp. Med. 199(2), 221-229 (2004).
95. Polesskaya A, Seale P, Rudnicki M: Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 113(7), 841-852 (2003).
96. Shackel NA, McGuinness PH, Abbott CA, Gorrell M D, McCaughan GW: Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 49(4), 565-576 (2001).
97. Monga SP, Pediaditakis P, Mule K, Stolz DB Michalopoulos GK: Changes in WNT/a-catenin pathway during regulated growth in rat liver regeneration. Hepatology 33(5), 1098-1109 (2001).
98. Surendran K, Simon T C: CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am.J. Physiol. Renal Physiol. 284(4), 653-662 (2003).
99. Watkins DN, Berman DM, Wang B et al.: Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422(6929), 313-317 (2003).
100. Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423(6937), 255-260 (2003).
101. Karhadkar S, Berman DM: Tissue repair and stem cell renewal in carcinogenesis. Nature 432(7015), 324-331 (2004).
102. Hope KJ, Jin L, Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity. Nature Immunol. 5, 738-743 (2004).
103. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737, (1997).
104. Yuan X, Curtin J, Xiong Y et al.: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392-9400 (2004).
105. Singh SK, Hawkins C, Clarke ID et al.: Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
106. Al-Hajj M, Wicha MS, Benito- Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
107. Bapat SA, Mali AM, Koppikar CB, Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65, 3025-3029 (2005).
108. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL: Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029-3035 (2003).
109. Harrison DE, Lerner CP: Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 78(5), 1237-1240 (1991).
110. Peters R, Leyvraz S, Perey L: Apoptotic regulation in primitive hematopoietic precursors. Blood 92(6), 2041-2052 (1998).
111. Scharenberg CW, Harkey MA, Torok- Storb B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99(2), 507-512 (2002).
112. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nature Rev.Cancer 5, 275-284 (2005).
113. Verma UN, Surabhi RM, Schmaltieg A, Becerra A, Gaynor RB: Small interfering RNAs directed against a-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9(4), 1291-1300 (2003).
114. Chen S, Guttridge DC, You Z et al.: Wnt-1 signaling inhibits apoptosis by activating a-catenin/T cell factor-mediated transcription. J. Cell Biol. 152, 87-96 (2001).
115. You L, He B, Xu Z et al.: An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 64, 5385-5389 (2004).
116. Mazieres J, You L, He B et al.: Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer 117(2), 326-332 (2005).
117. Lepourcelet M, Chen Y, France D et al.: Small-molecule antagonists of the oncogenic Tcf/a-catenin protein complex. Cancer Cell 5(1), 91-102 (2004).
118. Emami KY, Nguyen C, Ma AH et al.: A small molecule inhibitor of betacatenin/ CREB-binding protein transcription. Proc. Natl Acad. Sci. USA 101(34), 12682-12687 (2004).
119. Dasgupta R, Kaykas A, Moon RT, Perrimon N: Functional genomic analysis of the Wnt-Wingless signaling pathway. Science 308, 826-833 (2005).